Why the study?
How should stable ischemic heart disease and acute coronary syndrome be managed in patients with hemophilia undergoing percutaneous coronary intervention?
How should stable ischemic heart disease and acute coronary syndrome be managed in patients with hemophilia undergoing percutaneous coronary intervention?
This case report and review provides guidance on balancing ischemic and bleeding risks during PCI in patients with hemophilia.
Case report offers hypothesis-generating guidance on PCI bleeding risk in hemophilia; prospective data needed before practice change.
Coronary artery disease (CAD), including stable ischemic heart disease (SIHD) and acute coronary syndrome (ACS), remains the leading cause of death in the US and one of the primary modalities used in the treatment of CAD is percutaneous coronary intervention (PCI). Despite the potential benefits of PCI in high risk CAD patients, the risk of hemorrhage presents a dilemma in the treatment of patients with hemophilia A and B. In an attempt to provide guidance on the management of SIHD and ACS in patients with hemophilia, we present the case of a patient with moderate hemophilia B and ACS who subsequently underwent PCI followed by a review of the associated literature.
No takes yet. Share an insight, caveat, or question.
Jabbar et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: